VIM and Autosomal recessive spastic ataxia of Charlevoix-Saguenay: Here, we used the striking phenotype of vimentin bundling as a biomarker of the disease state to assess the efficacy of a C-terminal-targeted Hsp90 inhibitor, KU-32, in treating ARSACS.